Investors sentiment increased to 1.15 in Q2 2019. Its up 0.13, from 1.02 in 2019Q1. It improved, as 10 investors sold Geron Corporation shares while 23 reduced holdings. 12 funds opened positions while 26 raised stakes. 57.77 million shares or 0.48% less from 58.05 million shares in 2019Q1 were reported.
Lpl Fincl Ltd Liability has invested 0% in Geron Corporation (NASDAQ:GERN). Creative Planning holds 0% or 119,031 shares in its portfolio. Amer Asset Management Incorporated has 20,000 shares for 0.02% of their portfolio. Susquehanna Llp holds 0% or 444,975 shares. Amalgamated Bancorporation, a New York-based fund reported 25,726 shares. Credit Suisse Ag has 136,498 shares for 0% of their portfolio. Jpmorgan Chase And holds 0% or 664,967 shares. California Public Employees Retirement Systems holds 0% or 106,800 shares in its portfolio. The Illinois-based Old Second Savings Bank Of Aurora has invested 0% in Geron Corporation (NASDAQ:GERN). Captrust has invested 0% of its portfolio in Geron Corporation (NASDAQ:GERN). Moreover, Hm Payson And has 0% invested in Geron Corporation (NASDAQ:GERN) for 500 shares. California State Teachers Retirement Systems stated it has 264,347 shares or 0% of all its holdings. Alliancebernstein Limited Partnership invested 0% of its portfolio in Geron Corporation (NASDAQ:GERN). Geode Management Lc reported 2.35M shares. Citigroup Inc, a New York-based fund reported 96,536 shares.
Geron Corporation (NASDAQ:GERN) Ratings Coverage
Among 3 analysts covering Geron (NASDAQ:GERN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Geron has $400 highest and $400 lowest target. $4’s average target is 168.46% above currents $1.49 stock price. Geron had 4 analyst reports since August 15, 2019 according to SRatingsIntel. The rating was maintained by FBR Capital on Tuesday, November 19 with “Buy”. Below is a list of Geron Corporation (NASDAQ:GERN) latest ratings and price target changes.
19/11/2019 Broker: FBR Capital Rating: Buy New Target: $4.0000 Maintain
31/10/2019 Broker: BidaskScore Rating: Hold Upgrade
03/09/2019 Broker: H.C. Wainwright Rating: Buy New Target: $4.0000 Initiates Coverage On
15/08/2019 Broker: Cantor Fitzgerald Rating: Overweight New Target: $4.0000 Initiates Coverage On
The stock decreased 0.67% or $0.01 during the last trading session, reaching $1.49. About 627,787 shares traded. Geron Corporation (NASDAQ:GERN) has declined 63.64% since December 4, 2018 and is downtrending. It has underperformed by 63.64% the S&P500.
Geron Corporation operates as a biopharmaceutical company. The company has market cap of $297.67 million. The firm supports the clinical stage development of a telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It currently has negative earnings. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.
More notable recent Geron Corporation (NASDAQ:GERN) news were published by: Seekingalpha.com which released: “Geron: Hold Despite Slim Premium As Promising Trials Await Funding – Seeking Alpha” on November 12, 2019, also Nasdaq.com with their article: “Earnings Preview: Geron (GERN) Q3 Earnings Expected to Decline – Nasdaq” published on October 31, 2019, Nasdaq.com published: “Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1% – Nasdaq” on November 07, 2019. More interesting news about Geron Corporation (NASDAQ:GERN) were released by: Seekingalpha.com and their article: “Geron: A Different Company – Seeking Alpha” published on November 13, 2019 as well as Globenewswire.com‘s news article titled: “Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) – GlobeNewswire” with publication date: November 21, 2019.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.